620 related articles for article (PubMed ID: 26572704)
61. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.
Itamochi H; Oumi N; Oishi T; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Clin Oncol; 2015 Oct; 20(5):967-73. PubMed ID: 25744580
[TBL] [Abstract][Full Text] [Related]
62. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
63. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
64. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
[TBL] [Abstract][Full Text] [Related]
65. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
Wilson MR; Reske JJ; Holladay J; Wilber GE; Rhodes M; Koeman J; Adams M; Johnson B; Su RW; Joshi NR; Patterson AL; Shen H; Leach RE; Teixeira JM; Fazleabas AT; Chandler RL
Nat Commun; 2019 Aug; 10(1):3554. PubMed ID: 31391455
[TBL] [Abstract][Full Text] [Related]
66. Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers
Khalique S; Nash S; Natrajan R
J Pathol; 2022 Sep; 258(1):1-3. PubMed ID: 35647895
[TBL] [Abstract][Full Text] [Related]
67. ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis.
Yachida N; Yoshihara K; Suda K; Nakaoka H; Ueda H; Sugino K; Yamaguchi M; Mori Y; Yamawaki K; Tamura R; Ishiguro T; Isobe M; Motoyama T; Inoue I; Enomoto T
Sci Rep; 2020 Aug; 10(1):14260. PubMed ID: 32868822
[TBL] [Abstract][Full Text] [Related]
68. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis.
Asaka S; Liu Y; Yu ZC; Rahmanto YS; Ono M; Asaka R; Miyamoto T; Yen TT; Ayhan A; Wang TL; Shih IM
Mod Pathol; 2023 Feb; 36(2):100045. PubMed ID: 36853791
[TBL] [Abstract][Full Text] [Related]
69. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.
Wu S; Fukumoto T; Lin J; Nacarelli T; Wang Y; Ong D; Liu H; Fatkhutdinov N; Zundell JA; Karakashev S; Zhou W; Schwartz LE; Tang HY; Drapkin R; Liu Q; Huntsman DG; Kossenkov AV; Speicher DW; Schug ZT; Van Dang C; Zhang R
Nat Cancer; 2021 Feb; 2(2):189-200. PubMed ID: 34085048
[TBL] [Abstract][Full Text] [Related]
70. ARID1A mutations in cancer development: mechanism and therapy.
Zhang X; Zhang Y; Zhao J; Wu Y; Zhang N; Shen W
Carcinogenesis; 2023 May; 44(3):197-208. PubMed ID: 36882165
[TBL] [Abstract][Full Text] [Related]
71. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
72. ARID1A loss in cancer: Towards a mechanistic understanding.
Mathur R
Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
[TBL] [Abstract][Full Text] [Related]
73. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.
Zhang X; Zhang Y; Yang Y; Niu M; Sun S; Ji H; Ma Y; Yao G; Jiang Y; Shan M; Zhang G; Pang D
Cancer Epidemiol; 2012 Jun; 36(3):288-93. PubMed ID: 21889920
[TBL] [Abstract][Full Text] [Related]
74. Dedifferentiated Ovarian Carcinoma with ARID1A and ARID1B Mutations: A Clinicopathological Report and Literature Review.
Kamal M; Atwi D; Pang H; Li S; Hassell L
Int J Surg Pathol; 2023 Dec; 31(8):1526-1531. PubMed ID: 36843546
[TBL] [Abstract][Full Text] [Related]
75. A key HDAC6 dependency of ARID1A-mutated ovarian cancer.
Altucci L
Nat Cell Biol; 2017 Jul; 19(8):889-890. PubMed ID: 28752851
[TBL] [Abstract][Full Text] [Related]
76. SMARCA4 loss irrelevant for
Wagner SK; Moon AS; Howitt BE; Renz M
Gynecol Oncol Rep; 2023 Dec; 50():101305. PubMed ID: 38033359
[TBL] [Abstract][Full Text] [Related]
77. EZH2 inhibition in
Alldredge JK; Eskander RN
Gynecol Oncol Res Pract; 2017; 4():17. PubMed ID: 29093822
[TBL] [Abstract][Full Text] [Related]
78. Landscape of chromatin remodeling gene alterations in endometrial carcinoma.
Momeni-Boroujeni A; Vanderbilt C; Yousefi E; Abu-Rustum NR; Aghajanian C; Soslow RA; Ellenson LH; Weigelt B; Murali R
Gynecol Oncol; 2023 May; 172():54-64. PubMed ID: 36958196
[TBL] [Abstract][Full Text] [Related]
79. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
[TBL] [Abstract][Full Text] [Related]
80. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Ogiwara H; Takahashi K; Sasaki M; Kuroda T; Yoshida H; Watanabe R; Maruyama A; Makinoshima H; Chiwaki F; Sasaki H; Kato T; Okamoto A; Kohno T
Cancer Cell; 2019 Feb; 35(2):177-190.e8. PubMed ID: 30686770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
